Velneperit
Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet
Shionogi · Phase 2 · Completed · Enrollment 842
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Placebo | n/r | n/r | n/r | n/r |
| S-2367 1600 mg q.d. 54 weeks | n/r | n/r | n/r | n/r |
| S-2367 1600 mg q.d. 60 weeks | n/r | n/r | n/r | n/r |
Not shown
- Placebo: endpoint not reported
- S-2367 1600 mg q.d. 54 weeks: endpoint not reported
- S-2367 1600 mg q.d. 60 weeks: endpoint not reported